Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

SAR131675

Catalog No: tcsc0970

Available Sizes

Size: 10mg

Size: 50mg

Specifications

CAS No:
1433953-83-3

Formula:
$C_{18}H_{22}N_4O_4$

Pathway:
Protein Tyrosine Kinase/RTK

Target:
VEGFR

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 28 mg/mL (78.13 mM)

Observed Molecular Weight:
358.39

Product Description

SAR131675 is a potent and selective **VEGFR3** inhibitor with an **IC_{50}** of 23 nM.

IC50 & Target: IC50: 23 nM (VEGFR3)[1]

In Vitro: AR131675 is highly selective for VEGFR-3 versus 107 receptors, enzymes, ion channels, and 65 kinases. However, it is moderately active on VEGFR-2 with a VEGFR-3/VEGFR-2 ratio of about 10. SAR131675 inhibits VEGFR-3 tyrosine kinase activity and

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

VEGFR-3 autophosphorylation in HEK cells with IC_{50} values of 20 and 45 nM, respectively. SAR131675 dose dependently inhibits the proliferation of primary human lymphatic cells, induced by the VEGFR-3 ligands VEGFC and VEGFD, with an IC_{50} of about 20 nM. SSAR131675 has no antiproliferative activity on a panel of 30 tumors and primary cells, further showing its high specificity and indicating that SAR131675 is not a cytotoxic or cytostatic agent[1].

In Vivo: SAR131675 is very well tolerated in mice and shows a potent antitumoral effect in several orthotopic and syngenic models, including mammary 4T1 carcinoma and RIP1.Tag2 tumors. Interestingly, it significantly reduces lymph node invasion and lung metastasis, showing its antilymphangiogenic activity *in vivo*. SAR131675 significantly reduces TAM infiltration and aggregation in 4T1 tumors[1].